Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Glycoprotein G / G

Glycoprotein G / G

Brief Information

Name:Thrombospondin 1
Target Synonym:TSP,Glycoprotein G,THBS1,Thrombospondin-1p180,TSP1,Thrombospondin-P50,Thrombospondin-1,THBS-1,TSP-1,THBS,Thrombospondin 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
RSG-V5221 HRSV HRSV (A) Glycoprotein G Protein, His Tag
ACRO Quality

Glycoprotein / GP (virus) Molecule Synonym Name

Glycoprotein GP55,Envelope glycoprotein B

Glycoprotein / GP (virus) Molecule Background

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus) References

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VT-1021 VT-1021 Phase 1 Clinical Vigeo Therapeutics Inc Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message